Deep Learning‐Enabled Multiplexed Point‐of‐Care Sensor using a Paper‐Based Fluorescence Vertical Flow Assay

• Published in: Small (Weinheim an der Bergstrasse, Germany) Vol. 19; no. 51; pp. e2300617 - n/a
• Main Authors: Goncharov, Artem, Joung, Hyou‐Arm, Ghosh, Rajesh, Han, Gyeo‐Re, Ballard, Zachary S., Maloney, Quinn, Bell, Alexandra, Aung, Chew Tin Zar, Garner, Omai B., Carlo, Dino Di, Ozcan, Aydogan
• Format: Journal Article
• Language: English
• Published: Germany Wiley Subscription Services, Inc 01.12.2023
• Subjects: Assaying; Biomarkers; cardiac biomarkers; Coefficient of variation; conjugated polymer nanoparticles; Creatine; Deep Learning; Fluorescence; Humans; Kinases; multiplexed sensing; Multiplexing; Myoglobins; Neural networks; paper‐based assays; Point-of-Care Systems; point‐of‐care sensing; Sensors; vertical flow assays; deep learning; multiplexed sensing; neural networks; point-of-care sensing; cardiac biomarkers; paper-based assays; conjugated polymer nanoparticles; vertical flow assays
• ISSN: 1613-6810; 1613-6829; 1613-6829
• DOI: 10.1002/smll.202300617

Multiplexed computational sensing with a point‐of‐care serodiagnosis assay to simultaneously quantify three biomarkers of acute cardiac injury is demonstrated. This point‐of‐care sensor includes a paper‐based fluorescence vertical flow assay (fxVFA) processed by a low‐cost mobile reader, which quantifies the target biomarkers through trained neural networks, all within <15 min of test time using 50 µL of serum sample per patient. This fxVFA platform is validated using human serum samples to quantify three cardiac biomarkers, i.e., myoglobin, creatine kinase‐MB, and heart‐type fatty acid binding protein, achieving less than 0.52 ng mL−1 limit‐of‐detection for all three biomarkers with minimal cross‐reactivity. Biomarker concentration quantification using the fxVFA that is coupled to neural network‐based inference is blindly tested using 46 individually activated cartridges, which shows a high correlation with the ground truth concentrations for all three biomarkers achieving >0.9 linearity and <15% coefficient of variation. The competitive performance of this multiplexed computational fxVFA along with its inexpensive paper‐based design and handheld footprint makes it a promising point‐of‐care sensor platform that can expand access to diagnostics in resource‐limited settings. A multiplexed point‐of‐care serodiagnosis assay is reported to simultaneously quantify three biomarkers of acute cardiac injury. This point‐of‐care sensor includes a paper‐based fluorescence vertical‐flow‐assay processed by a low‐cost mobile reader, which quantifies the target biomarkers using neural networks within <15 min per test using 50 µL of serum sample per patient.